Literature DB >> 535672

Coagulation abnormalities in diabetic coma before and 24 hours after treatment.

E H McLaren, D R Cullen, M J Brown.   

Abstract

A coagulation screen consisting of measurement of the prothrombin time, thrombin time, kaolin caphalin clotting time, platelet count, plasma fibrinogen level, fibrin degradation products and ethanol gelation test was performed on 24 patients with impairment of consciousness due to acute diabetic metabolic decompensation at the start of treatment and 24 hours later. 22 out of 24 patients showed at least one coagulation abnormality on admission of which the commonest were a prolonged prothrombin time, shortened kaolin cephalin clotting.time and raised plasma fibrinogen level. After 24 hours of treatment these values were more normal but 20 out of 22 patients still displayed some abnormality. 15 patients had two or more coagulation abnormalities on admission including 3 patients with haematological abnormalities suggestive of disseminated intravascular coagulation. This group was older and had higher blood ureas than those with fewer abnormalities, but plasma glucose, sodium, potassium and bicarbonate levels were similar in both groups of patients. All 5 patients with hyperosmolar non-ketotic coma and all 3 patients who died without recovering consciousness had two or more coagulation abnormalities on admission.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 535672     DOI: 10.1007/BF01236267

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  10 in total

1.  THE BLOOD COAGULABILITY IN DIABETIC PATIENTS.

Authors:  O EGEBERG
Journal:  Scand J Clin Lab Invest       Date:  1963       Impact factor: 1.713

2.  A quick and accurate method for the determination of fibronogen in plasma.

Authors:  B C ELLIS; A STRANSKY
Journal:  J Lab Clin Med       Date:  1961-09

3.  Successful treatment of disseminated intravascular coagulopathy complicating diabetic coma.

Authors:  G Nicholson; G H Tomkin
Journal:  Br Med J       Date:  1974-11-23

4.  Cerebral intravascular coagulation in diabetic ketoacidosis.

Authors:  W R Timperley; F E Preston; J D Ward
Journal:  Lancet       Date:  1974-05-18       Impact factor: 79.321

5.  Correlative study of blood coagulation and serum lipids in diabetics without clinically recognizable complications.

Authors:  M H Ghanem; S Tawfik; F K Guirgis; M el-Sawy
Journal:  Atherosclerosis       Date:  1971 Sep-Oct       Impact factor: 5.162

6.  Evaluation of a rapid method for the determination of plasma fibrinogen.

Authors:  H B Burmester; K Aulton; G I Horsfield
Journal:  J Clin Pathol       Date:  1970-02       Impact factor: 3.411

7.  Platelet adhesiveness, plasma fibrinogen and factor 8 levels in diabetes mellitus.

Authors:  E E Mayne; J M Bridges; J A Weaver
Journal:  Diabetologia       Date:  1970-08       Impact factor: 10.122

8.  Disseminated intravascular coagulation in diabetes mellitus, with reference to the role of increased platelet aggregation.

Authors:  H C Kwaan; J A Colwell; N Suwanwela
Journal:  Diabetes       Date:  1972-02       Impact factor: 9.461

9.  Standardization of the one-stage prothrombin time for the control of anticoagulant therapy.

Authors:  R Biggs; K W Denson
Journal:  Br Med J       Date:  1967-01-14

Review 10.  Neurologic manifestations of diabetic comas: correlation with biochemical alterations in the brain.

Authors:  R Guisado; A I Arieff
Journal:  Metabolism       Date:  1975-05       Impact factor: 8.694

  10 in total
  2 in total

1.  Antiplatelet/anticoagulant drug therapy in severely uncontrolled diabetes mellitus.

Authors:  P Carroll; R Matz
Journal:  Diabetologia       Date:  1983-04       Impact factor: 10.122

2.  Increased alpha 2-macroglobulin in diabetes: a hyperglycemia related phenomenon associated with reduced antithrombin III activity.

Authors:  A Ceriello; D Giugliano; A Quatraro; A Stante; P Dello Russo; R Torella
Journal:  Acta Diabetol Lat       Date:  1989 Apr-Jun
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.